Transcription Factors in Cancer Development and Therapy
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Cancer is a multi-step process and requires constitutive expression/activation of transcription factors (TFs) for growth and survival. Many of the TFs reported so far are critical for carcinogenesis. These include pro-inflammatory TFs, hypoxia-inducible factors (HIFs), cell proliferation and epithelial–mesenchymal transition (EMT)-controlling TFs, pluripotency TFs upregulated in cancer stem-like cells, and the nuclear receptors (NRs). Some of those, including HIFs, Myc, ETS-1, and β-catenin, are multifunctional and may regulate multiple other TFs involved in various pro-oncogenic events, including proliferation, survival, metabolism, invasion, and metastasis. High expression of some TFs is also correlated with poor prognosis and chemoresistance, constituting a significant challenge in cancer treatment. Considering the pivotal role of TFs in cancer, there is an urgent need to develop strategies targeting them. Targeting TFs, in combination with other chemotherapeutics, could emerge as a better strategy to target cancer. So far, targeting NRs have shown promising results in improving survival. In this review, we provide a comprehensive overview of the TFs that play a central role in cancer progression, which could be potential therapeutic candidates for developing specific inhibitors. Here, we also discuss the efforts made to target some of those TFs, including NRs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Samanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421438111 · Cited by 460 · cited 2×
“HIF-1α is associated with the survival of the CSCs [68,69], and for the acquisition of chemoresistance [70].”
BackgroundRetractedMantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399 · cited 1×
“STAT3 plays a very crucial role in the initiation and progression of cancer by promoting a pro-carcinogenic inflammatory microenvironment [30,31], while suppressing anti-tumor immunity [32].”
BackgroundThe nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964 · cited 1×
“NRs are a family of ligand-regulated TFs that possess a DNA-binding domain and a C-terminal ligand-binding domain that interacts with the ligands such as estrogen and progesterone to regulate the transcription in some hormone-sensitive tumors including breast, ovarian and prostate cancer [128,129].”
BackgroundA cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783 · cited 9×
“Most of t e c rrent therapeutic options available or under-study are focused on targeting these oncogenic TFs. Figure 1. c e tic i r re rese ti g the transcription factors activated in cancer to regulate the expression of genes involved in tu or gro th, etastasis, che oresistance, epithelial– esenchy al transition (E…”
BackgroundInfluentialCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“In most solid tumors, the rapidly growing cells generate regions of hypoxia because of aberrant vascularization and inadequate oxygen [41], which often lead to more aggressive tumor behaviors [42,43], therapy resistance and poor prognosis [44,45].”
BackgroundSTATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 1×
“STAT3 plays a very crucial role in the initiation and progression of cancer by promoting a pro-carcinogenic inflammatory microenvironment [30,31], while suppressing anti-tumor immunity [32].”
BackgroundRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846 · cited 1×
“ETS TFs are considered as major oncodrivers, linking family members FL1 in Ewing sarcoma, ETS in leukemia [100], and ERG gene fusion in prostate cancer [101].”
BackgroundAP-1 as a regulator of cell life and death
Shaulian, E., & Karin, M. (2002) · Nature Cell Biology · doi:10.1038/ncb0502-e131 · Cited by 2,961 · cited 1×
“For example, AP1 target genes FasL, Bim, or Bcl3 could be either positive or negative regulators of apoptosis, and the balance between the pro- and anti-apoptotic target genes determines the final outcome of AP1, whether the cell will survive or undergo death [27,28].”
BackgroundLlovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Human papillomavirus and cervical cancer
Burd, E. M. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.1.1-17.2003 · Cited by 2,420 · cited 1×
“Chronic inflammation caused by chemical and physical agents [14] and chronic virus infection such as human papillomavirus in cervical cancer [15] and hepatitis B and C in hepatocellular carcinoma (HCC) [16,17] increases the risk of malignancy.”
BackgroundDPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Zhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070 · cited 1×
“Several inflammatory factors encoded by NF-κB target genes, specifically interleukin-6 (IL-6), are important STAT3 activators [22,33].”
BackgroundInhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946
Liu, Z.-G., Hsu, H., Goeddel, D. V., & Karin, M. (1996) · Cell · doi:10.1016/s0092-8674(00)81375-6 · Cited by 1,937
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575 · cited 1×
“Mutation of upstream signaling pathways, chromosomal rearrangements, insertion of retroviral promoter and enhancer, activation of super-enhancers within its own gene, can lead to the induction of Myc expression in cancer [76].”
BackgroundHypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R. E., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.018 · Cited by 1,354 · cited 1×
“Both HIF-1α and HIF-2α are essential for CSC maintenance [66,67] and are required for different functions.”
BackgroundOverall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Nuclear Receptors, RXR, and the Big Bang
Evans, R. M., & Mangelsdorf, D. J. (2014) · Cell · doi:10.1016/j.cell.2014.03.012 · Cited by 1,200
Sibling rivalry in the E2F family
Trimarchi, J. M., & Lees, J. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm714 · Cited by 1,158 · cited 1×
“These activated CDKs then phosphorylate pRB proteins, resulting in the release of E2F and subsequent G1-S- transition [89,90].”
BackgroundSlamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
c-Myc transactivation of LDH-A : Implications for tumor metabolism and growth
Shim, H., Dolde, C., Lewis, B. C., Wu, C.-S., Dang, G., Jungmann, R. A., Dalla-Favera, R., & Dang, C. V. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6658 · Cited by 1,092
Ema, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y., & Fujii-Kuriyama, Y. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4273 · Cited by 1,016
Bollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, Ö., Schwitalla, S., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.002 · Cited by 946 · cited 1×
“STAT3 plays a very crucial role in the initiation and progression of cancer by promoting a pro-carcinogenic inflammatory microenvironment [30,31], while suppressing anti-tumor immunity [32].”
BackgroundDarolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815671 · Cited by 930 · cited 1×
“A phase III study concluded that in men with nonmetastatic-CRPC (nmCRPC), metastasis-free survival was significantly longer with darolutamide than with placebo [222].”
BackgroundTargeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919 · cited 1×
“Different approaches, including targeting NR ligand-binding domains, essential protein–protein interactions, modulating proteasomal degradation of TFs, disrupting TFs-DNA binding, targeting activity by modulation of post-translational modifications, have been utilized [140].”
MethodHeddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9701 · Cited by 813 · cited 1×
“Forced expression of non-degradable HIF2α is suggested to induce NANOG, OCT4, and c-Myc in non-CSCs in glioblastoma to promote survival and metastasis [73].”
BackgroundRetinoic acid in development: Towards an integrated view
Niederreither, K., & Dollé, P. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2340 · Cited by 726 · cited 1×
“Retinoids, which are precursors of vitamin A, function as the endogenous ligands for both RARs and RXRs, and are involved in mediating various physiological processes [240].”
BackgroundHypoxia and Metabolic Adaptation of Cancer Cells
Eales, K. L., Hollinshead, K. E. R., & Tennant, D. A. (2016) · Oncogenesis · doi:10.1038/oncsis.2015.50 · Cited by 724 · cited 1×
“In most solid tumors, the rapidly growing cells generate regions of hypoxia because of aberrant vascularization and inadequate oxygen [41], which often lead to more aggressive tumor behaviors [42,43], therapy resistance and poor prognosis [44,45].”
BackgroundHypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α
Soeda, A., Park, M., Lee, D., Mintz, A., Androutsellis-Theotokis, A., McKay, R. D., Engh, J., Iwama, T., Kunisada, T., Kassam, A. B., et al. (2009) · Oncogene · doi:10.1038/onc.2009.252 · Cited by 656
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624 · cited 1×
“Digoxin (a cardiac glycoside), used for treating congestive heart failure and arrhythmias, also inhibit HIF-1α synthesis and show anti-cancer effects [157] and is in phase II of a clinical trial.”
BackgroundConstitutively activated Jak-STAT pathway in T cells transformed with HTLV-I
Migone, T.-S., Lin, J.-X., Cereseto, A., Mulloy, J. C., O'Shea, J. J., Franchini, G., & Leonard, W. J. (1995) · Science · doi:10.1126/science.7604283 · Cited by 557
STAT3 Plays a Critical Role in KRAS -Induced Pancreatic Tumorigenesis
Corcoran, R. B., Contino, G., Deshpande, V., Tzatsos, A., Conrad, C., Benes, C. H., Levy, D. E., Settleman, J., Engelman, J. A., & Bardeesy, N. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0908 · Cited by 413 · cited 1×
“STAT3 is involved in various stages of pancreatic cancer, and given its role in driving PDAC progression, it is considered an important therapeutic target [40].”
BackgroundYang, B.-S., Hauser, C. A., Henkel, G., Colman, M. S., Beveren, C. V., Stacey, K. J., Hume, D. A., Maki, R. A., & Ostrowski, M. C. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.2.538 · Cited by 333 · cited 1×
“The founding member of the family ETS1 can be phosphorylated by MAPK, which increases its transcriptional activity [102].”
BackgroundMitotic and mitogenic Wnt signalling
Niehrs, C., & Acebron, S. P. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.124 · Cited by 305 · cited 1×
“The activation of Wnt/β-catenin signaling in cancer plays a central role in the cell cycle and contributes to the neoplastic transformation through two of its main downstream targets, c-Myc and Cyclin D1 [118].”
BackgroundBronte-Tinkew, D. M., Terebiznik, M., Franco, A., Ang, M., Ahn, D., Mimuro, H., Sasakawa, C., Ropeleski, M. J., Peek, R. M., & Jones, N. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1191 · Cited by 154
PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells
Sun, S., & Steinberg, B. M. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-7-1651 · Cited by 101 · cited 1×
“Many tumor viruses such as hepatitis B virus [36], human papillomavirus [37], human T-lymphotropic virus type 1 [38], Epstein–Barr virus [39] also activate STAT3 by distinct mechanisms.”
BackgroundLiu, Y., Ye, X., Zhang, J.-B., Ouyang, H., Shen, Z., Wu, Y., Wang, W., Wu, J., Tao, S., Yang, X., et al. (2015) · Oncogene · doi:10.1038/onc.2015.7 · Cited by 93
Choudhari, S. R., Khan, M. A., Harris, G., Picker, D., Jacob, G. S., Block, T., & Shailubhai, K. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0561 · Cited by 90
Sapra, P., Kraft, P., Pastorino, F., Ribatti, D., Dumble, M., Mehlig, M., Wang, M., Ponzoni, M., Greenberger, L. M., & Horak, I. D. (2011) · Angiogenesis · doi:10.1007/s10456-011-9209-1 · Cited by 70 · cited 2×
“A phase I study of EZN-2208 (NCT01251926) in patients with neuroblastoma showed low toxicity and was associated with clinical benefits [155].”
BackgroundEts-1 regulates energy metabolism in cancer cells
Verschoor, M. L., Wilson, L. A., Verschoor, C. P., & Singh, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013565 · Cited by 59
Epstein-Barr virus-derived EBNA2 regulates STAT3 activation
Muromoto, R., Ikeda, O., Okabe, K., Togi, S., Kamitani, S., Fujimuro, M., Harada, S., Oritani, K., & Matsuda, T. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.11.053 · Cited by 42 · cited 1×
“Many tumor viruses such as hepatitis B virus [36], human papillomavirus [37], human T-lymphotropic virus type 1 [38], Epstein–Barr virus [39] also activate STAT3 by distinct mechanisms.”
BackgroundWu, J., Contratto, M., Shanbhogue, K. P., Manji, G. A., O’Neil, B. H., Noonan, A., Tudor, R., & Lee, R. (2019) · World Journal of Clinical Oncology · doi:10.5306/wjco.v10.i3.149 · Cited by 41 · cited 1×
“RO7070179 has been suggested to potentially benefit HCC patients [156].”
Background
Cited by
SLC4A4 promotes prostate cancer progression in vivo and in vitro via AKT-mediated signalling pathway
Liu, Z., Wang, Q., Zhai, G., Ke, S., Yu, X., & Guo, J. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02546-6 · Cited by 22
Sadalge, D., Clasman, J. R., Topal, S., Musser, D., Von der Porten, L., Wu, S., Schultz, S. E., Austin, W., Huang, D., Gao, Y.-D., et al. (2025) · doi:10.1101/2025.08.01.667454 · Cited by 2
Metadata
- Authors
- Vishnoi, K., Viswakarma, N., Rana, A., & Rana, B.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-08-15
- Volume
- 12
- Issue
- 8
- Pages
- 2296
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3049103650
- Cited by
- 164
- References
- 43
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.